Latest LLY news

China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion

Reuters · Thu, 24 Sep 2026 00:21:21 -0400

Chinese drugmaker InnoCare ‌Pharma said on Thursday it entered ⁠into a research collaboration and license agreement with Eli Lilly ‌that ⁠could be worth up to ⁠about $3.35 billion.

Could Retatrutide Be Worth $10 Billion to Eli Lilly?

The Motley Fool · Wed, 23 Sep 2026 13:45:01 -0400

Eli Lilly has a deep pipeline in its core therapeutic area. Its next-gen obesity drug, retatrutide, posted excellent results in Phase 3 studies.

Viking's Obesity Edge May Be Staying Power, Not Weight Loss

MarketBeat · Wed, 23 Sep 2026 13:22:25 -0400

Viking Therapeutics NASDAQ: VKTX stock jumped 36% on Sept. 22. The catalyst was new maintenance data for VK2735, its GLP-1/GIP obesity candidate, which showed that patients maintained most of their weight loss after switching from weekly shots to every-other-week or monthly dosing.

Eli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Year

24/7 Wall Street · Wed, 23 Sep 2026 11:32:35 -0400

Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceutical capital. The answer depends on a trade-off most investors get wrong.

Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up?

MarketBeat · Wed, 23 Sep 2026 09:17:18 -0400

To see whether Novo Nordisk NYSE: NVO is closing the gap with competitor Eli Lilly NYSE: LLY in the GLP-1 market, investors need only look at patent-cliff timing and current market share. Eli Lilly commands a larger and growing market share and stands to keep exclusivity years longer than Novo.

Oura's $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring

MarketBeat · Tue, 22 Sep 2026 14:26:07 -0400

Oura Inc. NASDAQ: OURA launched its roadshow on Sept. 21, 2026, targeting a Nasdaq debut under the ticker OURA during the week of Sept.

Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer

Benzinga · Tue, 22 Sep 2026 13:43:05 -0400

The U.S. Food and Drug Administration (FDA) on Friday granted full approval to Eli Lilly and Co.'s (NYSE:LLY) Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for pretreated breast cancer patients.

Market information is provided for research and visualization and is not investment advice.